BioCentury
ARTICLE | Clinical News

Vical completes Allovectin-7 enrollment

September 19, 2001 7:00 AM UTC

VICL completed enrollment of 200 chemotherapy-naive patients in its Phase III trial of Allovectin-7 to treat metastatic melanoma. According to VICL, the FDA said that robust time to disease progressio...